List of Excipients in Branded Drug OFEV

OFEV Excipient Strategy and Commercial Opportunities for Nintedanib

Last updated: August 12, 2026

OFEV is a high-value oral nintedanib product built around a lipid-based soft-capsule formulation. Its excipient profile creates opportunities in generic formulation development, low-cost capsule manufacture, pediatric delivery, gastrointestinal tolerability, and differentiated fixed-dose or modified-release systems. The main commercial constraint is that excipient substitution does not by itself avoid patents covering nintedanib, its salts, pharmaceutical compositions, or therapeutic uses.

What is OFEV and which dosage forms use excipients?

OFEV contains nintedanib esylate, a small-molecule tyrosine kinase inhibitor marketed by Boehringer Ingelheim. In the United States, the product is supplied as 100 mg and 150 mg soft gelatin capsules. The approved indications include idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases with a progressive phenotype, and systemic sclerosis-associated interstitial lung disease.[1]

The commercial formulation uses a lipid-based fill rather than a conventional compressed tablet. This choice addresses the limited aqueous solubility of nintedanib and supports oral exposure.

Product attribute	OFEV profile
Active ingredient	Nintedanib esylate
Dosage form	Soft gelatin capsule
Strengths	100 mg and 150 mg
Standard adult dose	150 mg twice daily
Dose reduction	100 mg twice daily
Main therapeutic areas	IPF, progressive fibrosing ILD, SSc-ILD
Primary formulation platform	Lipid-based soft capsule
Administration	With food
Key adverse-event concern	Diarrhea and gastrointestinal intolerance
U.S. regulatory pathway	New drug application
Biosimilar pathway	Not applicable

The prescribing information directs patients to take OFEV with food. Food administration is commercially important because it supports tolerability and may improve the consistency of exposure for a formulation with a lipid-based fill.[1]

What excipients are used in OFEV capsules?

The U.S. label identifies a lipid-based capsule fill and gelatin shell system. The inactive ingredients include triglycerides, hard fat, and lecithin in the capsule fill. The shell contains gelatin, glycerol, titanium dioxide, and iron oxide colorants, with the exact colorant profile varying by capsule strength.[1]

Formulation component	Functional role	Commercial relevance
Triglycerides	Lipid vehicle and solvent system	Supports dissolution and oral absorption
Hard fat	Solid lipid and consistency modifier	Controls fill properties and capsule processing
Lecithin	Surfactant and wetting aid	Supports dispersion of the active ingredient
Gelatin	Soft capsule shell polymer	Enables encapsulation of the lipid fill
Glycerol	Plasticizer	Controls shell flexibility and mechanical performance
Titanium dioxide	Opacifier and color aid	Supports product appearance and light protection
Iron oxides	Colorants	Supports strength differentiation and product identification

The excipient system is relatively compact. That is commercially useful because it reduces the number of components requiring qualification, but it also limits the freedom available to a generic developer seeking a low-cost or non-infringing formulation.

How does the OFEV lipid formulation affect excipient strategy?

The formulation strategy is based on improving the apparent solubility and dispersion of nintedanib. A generic developer must control several linked variables:

1. Nintedanib esylate loading and physical state.
2. Lipid vehicle selection.
3. Surfactant concentration.
4. Fill viscosity.
5. Capsule-shell compatibility.
6. Dissolution after exposure to gastrointestinal fluids.
7. Chemical and physical stability during storage.

A formulation that matches the labeled dose but fails to reproduce dissolution or exposure characteristics can create bioequivalence risk. Lipid formulations also require control of precipitation after dilution in gastrointestinal fluid. A formulation can show strong in vitro solubilization while producing variable in vivo absorption if the drug precipitates after digestion.

For this reason, excipient selection should be evaluated through a combination of:

• equilibrium and kinetic solubility;
• dispersion and precipitation testing;
• biorelevant dissolution;
• lipid digestion studies;
• capsule-shell migration testing;
• accelerated stability;
• extractables and leachables analysis;
• fed and fasted pharmacokinetic studies.

The highest-value formulation work is likely to involve the lipid vehicle and surfactant system rather than simple colorant substitution.

What excipient substitutions offer the strongest generic opportunities?

The strongest opportunities are formulation changes that maintain exposure while improving manufacturability, cost, patient usability, or supply security.

Alternative lipid vehicles

A generic developer could evaluate medium-chain triglycerides, long-chain triglycerides, mixed glycerides, or other pharmaceutically accepted lipid systems. The goal would be to preserve nintedanib solubilization without copying the reference product’s precise composition.

Potential benefits include lower raw-material cost, improved supply continuity, or better capsule-fill processing. The primary risks are precipitation, oxidation, fill leakage, and altered food effects.

Alternative surfactants

Lecithin is central to the reference formulation, but alternative surfactants may improve wetting or digestion performance. Candidate classes could include nonionic surfactants and co-solvent systems, subject to regulatory acceptability and toxicological limits.

The commercial advantage would be highest if the substitute reduces fill volume or improves dissolution at the 100 mg strength. The principal risk is gastrointestinal intolerance, which is already a major limitation of nintedanib treatment.

Hard-shell or tablet alternatives

A tablet or hard capsule could reduce manufacturing complexity and improve line efficiency. That route is technically more difficult because it may require amorphous dispersion, nanosizing, cyclodextrin complexation, or another enabling technology.

A successful tablet could support:

• lower unit manufacturing cost;
• easier dose splitting or combination packaging;
• improved supply-chain efficiency;
• more flexible pediatric dose design.

The development burden would be materially higher than for a soft-capsule generic because the product would need to establish comparable bioavailability through a different delivery platform.

Shell and colorant changes

Shell colorants and opacity agents are lower-value differentiation areas. A generic developer can generally seek a distinct appearance, provided the product complies with FDA labeling, color additive, and identification requirements.

These changes can reduce dependence on specific colorant suppliers, but they are unlikely to create a durable commercial advantage. They may also create product-recognition issues for patients and pharmacists.

What formulations are protected by patents?

Patent protection for nintedanib can extend beyond the active ingredient. Relevant claim categories may include:

• nintedanib and pharmaceutically acceptable salts;
• crystalline or polymorphic forms;
• pharmaceutical compositions;
• oral dosage forms;
• lipid or solubilizing systems;
• methods of treating pulmonary fibrosis;
• dosing regimens and dose-reduction methods;
• use in specific interstitial lung disease populations.

An excipient change is commercially useful only if it achieves both regulatory equivalence and a defensible freedom-to-operate position. A composition patent may capture a formulation by functional limitations, concentration ranges, excipient classes, or performance characteristics rather than by naming every excipient.

A generic developer should therefore distinguish between:

IP question	Relevance to excipient strategy
Does a patent claim nintedanib esylate itself?	May block all products until expiry unless invalidated
Does a claim cover a lipid composition?	May constrain vehicle and surfactant selection
Does a claim cover a dosage regimen?	May affect labeling and Paragraph IV strategy
Does a claim cover a disease indication?	May require a skinny-label approach
Does a claim cover manufacturing?	May affect API or fill-process sourcing
Does a patent use functional language?	May capture non-identical excipient systems

When does OFEV lose exclusivity?

OFEV’s U.S. market protection is layered. FDA approval exclusivity and patent protection are separate rights, and the commercial entry date depends on the last enforceable barrier affecting the proposed generic product and labeling.

Protection category	OFEV relevance
Small-molecule regulatory exclusivity	Applies under the Hatch-Waxman framework
Orphan exclusivity	Relevant to specific qualifying indications
Orange Book patents	Can trigger a 30-month stay after a Paragraph IV notice
Method-of-use patents	May require indication carve-outs
Composition and formulation patents	May affect all or selected dosage forms
Biosimilar exclusivity	Not relevant because nintedanib is a small molecule

OFEV received U.S. approval in 2014 for idiopathic pulmonary fibrosis. The product later received approvals for systemic sclerosis-associated ILD and progressive fibrosing ILD.[1,2] Orphan exclusivity is indication-specific and does not automatically block every generic use of the active ingredient.

The controlling commercial question is not simply when the first OFEV patent expires. It is whether a proposed generic can launch with its selected formulation and label without infringing an enforceable patent or triggering a litigation delay.

What is the Orange Book status of OFEV?

OFEV is an FDA-approved small-molecule product subject to the Orange Book framework. Listed patents can cover the drug substance, drug product, or method of use.[3]

A prospective ANDA sponsor should review:

• current Orange Book patent listings;
• patent-use codes;
• expiration dates;
• pediatric extensions;
• terminal disclaimers;
• patent delisting disputes;
• any FDA regulatory exclusivity remaining for specific indications.

The Orange Book analysis should be performed at the strength and dosage-form level. A soft-capsule generic may face a different risk profile from a tablet or other dosage form because composition and manufacturing claims can be dosage-form-specific.

Which companies are challenging OFEV exclusivity?

Public generic entry risk should be assessed through FDA ANDA activity, Paragraph IV litigation, district-court filings, and commercial announcements. The principal competitive field is likely to include large generic manufacturers with experience in lipid-filled soft capsules, as well as specialty suppliers capable of producing non-reference formulations.

A Paragraph IV challenge could target:

• invalidity of listed composition patents;
• non-infringement based on a different excipient system;
• lack of patent enforceability;
• non-infringement based on a carved-out label;
• absence of infringement by a tablet or hard-capsule product.

The absence of a publicly identified challenger should not be treated as evidence that the estate is commercially impenetrable. Generic sponsors often conduct formulation and patent work before filing litigation or publicly disclosing launch plans.

How strong is the OFEV patent estate?

The estate is strongest where it combines active-ingredient claims with clinically important use claims. Formulation patents are most valuable when they are difficult to design around and when the product depends on a narrow performance window.

The estate is weaker if:

• the reference formulation can be replaced without a meaningful exposure penalty;
• the claims require narrow excipient ranges;
• alternative dosage forms are feasible;
• method-of-use claims can be carved out;
• earlier publications disclose the relevant lipid systems;
• the patents rely heavily on predictable excipient combinations.

From a formulation perspective, the commercial risk is likely to be concentrated in composition and use patents rather than in the listed colorants or basic capsule-shell materials.

What generic launch scenarios exist for OFEV?

Scenario 1: Reference-like soft capsule

A generic developer uses a similar lipid-fill architecture but changes excipient grades or ratios. This is the lowest technical-risk route and may support an ANDA with conventional bioequivalence work. It carries the highest risk of composition-patent overlap.

Scenario 2: Non-infringing lipid soft capsule

The sponsor develops a materially different lipid and surfactant system. This approach can improve freedom to operate but increases formulation and clinical risk.

Scenario 3: Tablet or hard capsule

A non-lipid dosage form could create a stronger differentiation position. The development timeline and bioequivalence burden would be higher, but the product could avoid some soft-capsule composition claims.

Scenario 4: Indication carve-out

A generic could omit patented methods of use while retaining non-protected indications. This strategy depends on the scope of the remaining FDA-approved indications and the wording of the patent-use codes.

What commercial opportunities exist beyond a generic OFEV?

Pediatric formulations

Nintedanib has a potential pediatric formulation opportunity because soft capsules are difficult for young children to swallow and dose flexibility is limited. A liquid, granule, dispersible tablet, or mini-capsule could improve administration.

The main technical obstacles are poor aqueous solubility, taste, dose uniformity, and gastrointestinal tolerability. A taste-masked multiparticulate system could be more commercially practical than a simple aqueous solution.

Lower-GI-burden formulations

Diarrhea is a major adverse effect associated with nintedanib. An excipient strategy that reduces local gastrointestinal drug concentration or moderates release could create clinical value, but any altered-release product would need to demonstrate comparable efficacy and safety.

Potential platforms include:

• enteric protection;
• delayed release;
• controlled release;
• lipid digestion modulation;
• lower-dose, higher-bioavailability systems.

These approaches may require a new drug application or a supplemental regulatory strategy rather than a straightforward ANDA.

Regional manufacturing and supply security

The soft-capsule platform creates opportunities for contract manufacturers with lipid-fill and gelatin-encapsulation capabilities. Regional production could reduce dependence on a limited supplier base for gelatin, triglycerides, lecithin, and specialty capsule components.

Non-animal shell options, such as hypromellose, could address religious, dietary, or sourcing requirements. However, replacing gelatin changes shell permeability, oxygen transmission, mechanical strength, and processing conditions. It is a development program, not a simple excipient substitution.

Combination products

Nintedanib is used in chronic fibrotic lung disease, where polypharmacy is common. A fixed-dose combination would face dose-flexibility, interaction, and regulatory hurdles. The more realistic opportunity is co-packaging with supportive therapies rather than a single combined dosage form.

How does OFEV compare with competing antifibrotic products?

Product	Active ingredient	Formulation profile	Excipient opportunity
OFEV	Nintedanib	Lipid-based soft capsule	Lipid substitution, pediatric delivery, shell alternatives
Esbriet	Pirfenidone	Oral capsules/tablets	Taste, dose frequency, tablet optimization
Generic pirfenidone	Pirfenidone	Multiple oral dosage forms	Cost and dose-packaging competition
Emerging antifibrotics	Various	Product-specific	May compete through tolerability and convenience

OFEV’s twice-daily dosing is commercially favorable relative to more frequent oral regimens, but diarrhea and food administration influence adherence. A formulation that maintains exposure with lower gastrointestinal burden could compete more effectively than a product offering only a lower price.

What patent litigation and settlement issues affect commercialization?

A Paragraph IV filing can lead to patent litigation and an automatic 30-month FDA approval stay under applicable Hatch-Waxman rules.[4] Settlement agreements may include delayed-entry dates, licenses, authorized-generic provisions, or restrictions tied to particular indications.

For an excipient-focused sponsor, settlement value depends on the scope of the formulation claims. A license covering one soft-capsule composition may leave room for a tablet or alternative lipid system. Conversely, a broad composition patent can make formulation differentiation commercially irrelevant until expiry or settlement entry.

Key Takeaways

• OFEV uses a lipid-based soft gelatin capsule containing triglycerides, hard fat, and lecithin, with gelatin, glycerol, titanium dioxide, and iron oxide colorants in the shell.[1]
• The highest-value excipient opportunities involve lipid vehicles, surfactants, precipitation control, and alternative dosage forms.
• Colorant and shell changes offer supply and branding benefits but limited strategic differentiation.
• Diarrhea creates a potential commercial opening for lower-GI-burden or modified-release products.
• Pediatric liquid, granule, mini-capsule, and taste-masked products are credible lifecycle opportunities.
• Nintedanib is a small molecule, so biosimilar competition is irrelevant. Hatch-Waxman ANDA and Paragraph IV strategies control generic entry.
• Excipient substitution does not eliminate exposure to composition, formulation, manufacturing, or method-of-use patents.
• The strongest generic position would combine bioequivalence, a non-infringing formulation, and a label that avoids protected uses.

FAQs

Can a generic manufacturer copy the OFEV excipients?

It can seek to use the same excipients, but the formulation may overlap composition or formulation patent claims. Regulatory similarity does not establish freedom to operate.

Is a nintedanib oral solution commercially feasible?

It is technically feasible but difficult because nintedanib has limited aqueous solubility, an unpleasant taste profile, and dose-uniformity requirements. A lipid-based dispersion or taste-masked multiparticulate product may be more practical.

Are gelatin-free OFEV alternatives commercially attractive?

Yes. A gelatin-free capsule could address dietary and supply-chain requirements, but shell permeability, mechanical performance, dissolution, and stability would require full development and regulatory validation.

Can excipients reduce nintedanib diarrhea?

They may alter dissolution, local concentration, or release, but a meaningful reduction in diarrhea would require clinical evidence. A simple excipient change cannot be assumed to improve tolerability.

Does OFEV have biosimilar competition?

No. Nintedanib is a chemically synthesized small molecule. Competitors would generally pursue generic-drug pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2024). OFEV (nintedanib) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

2. European Medicines Agency. (2024). Ofev: EPAR product information. European Union.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards. FDA.